 SAN JOSE, Calif., Aug. 30, 2021 PRNewswire -- Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration FDA has cleared the Investigational New Drug IND application for its CAR-T Chimeric Antigen Receptor-T cell therapy, which is being developed in partnership with Moffitt Cancer Center Moffitt. 